miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 24, 2025

Byline Bancorp anticipates crossing $10B asset threshold in Q1 2026 while maintaining strong capital and loan growth

View original at seekingalpha.com
Byline Bancorp anticipates crossing $10B asset threshold in Q1 2026 while maintaining strong capital and loan growth Earnings Call Insights: Byline Bancorp, Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Deposit outflows in DDA are driven by seasonality

    80% confidence
  • Company is open to disciplined M&A deals that make sense, has capital to be opportunistic and believes it can deliver strong financial results without needing to force a deal

    80% confidence
  • Noninterest income totaled $15.9 million in Q3, up 9.5% from last quarter, primarily due to $7 million gain on sale of loans driven by higher volumes

    80% confidence
  • With market expectations of 2 Fed cuts in Q4, net interest income expected to be $97 million to $99 million

    80% confidence
  • Fixed rate loan maturities for 2026 are roughly $750 million

    80% confidence
  • Loans grew 6% linked quarter and 11% year-to-date, ending at $7.5 billion; deposits totaled $7.8 billion, up 1% linked quarter and 7% year-to-date

    80% confidence
  • Commercial payments team focuses on businesses that originate a lot of ACH transactions and process payroll, with impact expected in 2026 and beyond

    80% confidence
  • Company is actively looking at M&A opportunities while prioritizing funding bank growth and maintaining capital for opportunistic deals

    80% confidence
  • During government shutdown, bank cannot sell and settle SBA loans and must hold them on balance sheet until government reopens

    80% confidence
  • The quarter marked 12 consecutive quarters of very strong financial performance for Byline and highlights the consistency of execution, resiliency of business model and optionality and flexibility in operating model

    80% confidence
  • Profitability metrics for the quarter were once again top quartile and credit quality continues to be stable to improving in some segments despite macroeconomic uncertainty, geopolitical tensions and government shutdown

    80% confidence
  • The margin expanded 9 basis points from last quarter to 4.27%, supported by improved deposit mix and higher asset yields

    80% confidence
  • Record net interest income of $99.9 million in Q3, up 4.1% from prior quarter, primarily due to organic loan growth and lower rates paid on deposits

    80% confidence
  • Durbin Amendment impact estimated at $4.5 million to $5 million annually, not going into effect until July 1 of the year following crossing the threshold

    80% confidence
  • Company anticipates crossing $10 billion asset threshold during Q1 2026, with Durbin and higher insurance assessments not taking effect until 2027

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Byline Bancorp anticipates crossing $10B asset threshold in Q1 2026 while maintaining strong capital and loan growth — Source | Via News | es.VIA.NEWS